$OKYO News

OKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain

OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug

OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

OKYO Pharma Announces First Patients Enrolled In Phase 3 NEPTUNE Trial Of Urcosimod For Neuropathic Corneal Pain

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

OKYO Pharma Announces Purchase of Shares by Director

OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

OKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per Share

OKYO Pharma Announces Purchase of Shares by Chairman

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

OKYO Pharma Says Gary Jacob, Chief Development Officer And Director, Increases His Holdings With Purchase Of 3,500 Ordinary Shares On NASDAQ At $1.40 Per Share